Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis.
Visceral leishmaniasis is a vector-borne protozoan infection that is fatal if untreated. There is no vaccination against the disease, and the current chemotherapeutic agents are ineffective due to increased resistance and severe side effects. Buparvaquone is a potential drug against the leishmaniase...
Published in: | PLOS Neglected Tropical Diseases |
---|---|
Main Authors: | , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021
|
Subjects: | |
Online Access: | https://doi.org/10.1371/journal.pntd.0009533 https://doaj.org/article/6b20bb80379e45a8848183c6952ee115 |
id |
ftdoajarticles:oai:doaj.org/article:6b20bb80379e45a8848183c6952ee115 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:6b20bb80379e45a8848183c6952ee115 2023-05-15T15:06:13+02:00 Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis. Rinez Thapa Subhasish Mondal Joakim Riikonen Jimi Rantanen Simo Näkki Tuomo Nissinen Ale Närvänen Vesa-Pekka Lehto 2021-06-01T00:00:00Z https://doi.org/10.1371/journal.pntd.0009533 https://doaj.org/article/6b20bb80379e45a8848183c6952ee115 EN eng Public Library of Science (PLoS) https://doi.org/10.1371/journal.pntd.0009533 https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0009533 https://doaj.org/article/6b20bb80379e45a8848183c6952ee115 PLoS Neglected Tropical Diseases, Vol 15, Iss 6, p e0009533 (2021) Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 article 2021 ftdoajarticles https://doi.org/10.1371/journal.pntd.0009533 2022-12-31T11:41:09Z Visceral leishmaniasis is a vector-borne protozoan infection that is fatal if untreated. There is no vaccination against the disease, and the current chemotherapeutic agents are ineffective due to increased resistance and severe side effects. Buparvaquone is a potential drug against the leishmaniases, but it is highly hydrophobic resulting in poor bioavailability and low therapeutic efficacy. Herein, we loaded the drug into silicon nanoparticles produced from barley husk, which is an agricultural residue and widely available. The buparvaquone-loaded nanoparticles were several times more selective to kill the intracellular parasites being non-toxic to macrophages compared to the pure buparvaquone and other conventionally used anti-leishmanial agents. Furthermore, the in vivo results revealed that the intraperitoneally injected buparvaquone-loaded nanoparticles suppressed the parasite burden close to 100%. By contrast, pure buparvaquone suppressed the burden only by 50% with corresponding doses. As the conclusion, the biogenic silicon nanoparticles are promising carriers to significantly improve the therapeutic efficacy and selectivity of buparvaquone against resistant visceral leishmaniasis opening a new avenue for low-cost treatment against this neglected tropical disease threatening especially the poor people in developing nations. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic PLOS Neglected Tropical Diseases 15 6 e0009533 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
spellingShingle |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 Rinez Thapa Subhasish Mondal Joakim Riikonen Jimi Rantanen Simo Näkki Tuomo Nissinen Ale Närvänen Vesa-Pekka Lehto Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis. |
topic_facet |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
description |
Visceral leishmaniasis is a vector-borne protozoan infection that is fatal if untreated. There is no vaccination against the disease, and the current chemotherapeutic agents are ineffective due to increased resistance and severe side effects. Buparvaquone is a potential drug against the leishmaniases, but it is highly hydrophobic resulting in poor bioavailability and low therapeutic efficacy. Herein, we loaded the drug into silicon nanoparticles produced from barley husk, which is an agricultural residue and widely available. The buparvaquone-loaded nanoparticles were several times more selective to kill the intracellular parasites being non-toxic to macrophages compared to the pure buparvaquone and other conventionally used anti-leishmanial agents. Furthermore, the in vivo results revealed that the intraperitoneally injected buparvaquone-loaded nanoparticles suppressed the parasite burden close to 100%. By contrast, pure buparvaquone suppressed the burden only by 50% with corresponding doses. As the conclusion, the biogenic silicon nanoparticles are promising carriers to significantly improve the therapeutic efficacy and selectivity of buparvaquone against resistant visceral leishmaniasis opening a new avenue for low-cost treatment against this neglected tropical disease threatening especially the poor people in developing nations. |
format |
Article in Journal/Newspaper |
author |
Rinez Thapa Subhasish Mondal Joakim Riikonen Jimi Rantanen Simo Näkki Tuomo Nissinen Ale Närvänen Vesa-Pekka Lehto |
author_facet |
Rinez Thapa Subhasish Mondal Joakim Riikonen Jimi Rantanen Simo Näkki Tuomo Nissinen Ale Närvänen Vesa-Pekka Lehto |
author_sort |
Rinez Thapa |
title |
Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis. |
title_short |
Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis. |
title_full |
Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis. |
title_fullStr |
Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis. |
title_full_unstemmed |
Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis. |
title_sort |
biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis. |
publisher |
Public Library of Science (PLoS) |
publishDate |
2021 |
url |
https://doi.org/10.1371/journal.pntd.0009533 https://doaj.org/article/6b20bb80379e45a8848183c6952ee115 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
PLoS Neglected Tropical Diseases, Vol 15, Iss 6, p e0009533 (2021) |
op_relation |
https://doi.org/10.1371/journal.pntd.0009533 https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0009533 https://doaj.org/article/6b20bb80379e45a8848183c6952ee115 |
op_doi |
https://doi.org/10.1371/journal.pntd.0009533 |
container_title |
PLOS Neglected Tropical Diseases |
container_volume |
15 |
container_issue |
6 |
container_start_page |
e0009533 |
_version_ |
1766337866431987712 |